Emerging IVD Companies
On June 13, the Supreme Court issued its long-awaited decision in Association for Molecular Pathology v. Myriad Pharmaceuticals, Inc. In a 9-0 decision, the Court ruled that naturally occurring human genes are not patent-eligible subject matter under the U.S. Patent Act, but cDNA can be patented. The Court did not address Myriad patents covering genetic testing methods based on specific mutations in human genes. The full decision is available online. The Myriad decision has caused a fair degree...
  HiberGene Diagnostics CEO Tony Hill As part of our new monthly series on emerging IVD companies, IVD Technology spoke with Tony Hill, CEO of HiberGene Diagnostics Ltd., a young company based in Dublin, Ireland. Hill's company has developed a rapid and highly sensitive molecular diagnostic test for bacterial meningitis, which the company hopes to introduce to the European market in Quarter 4 of this year, with a U.S. introduction a year later.   Please give us...
  Consumers worried about their risk for osteoporosis soon will have a new resource at their fingertips. By the end of Q2 2013, Crescent Diagnostics' CEO Brendan Farrell Crescent Diagnostics (Dublin) will launch its Bone Quality Test (BQT), which measures keratin levels in nail clippings as a surrogate marker for collagen, an indicator of bone quality. The consumer-to-lab kit initially will be available in Ireland and the United Kingdom, with other European markets, notably...
Stephen Lundy of Venaxis Inc. (formerly AspenBio Pharma) Any parent who has rushed to Urgent Care with a toddler shrieking in abdominal pain will appreciate the big opportunity Stephen Lundy saw when he became head of Venaxis Inc. (formerly AspenBio Pharma). A 25-year veteran of the IVD industry, Lundy says the market potential of the appendicitis blood test that the company was developing lured him from his CEO post at MicroPhage to Venaxis’s Colorado headquarters. When Lundy...
The Clinical Lab Expo will feature new science and technology in every area of clinical diagnostics, automation, information systems, point of care, OEM, and biotech. Roughly 750 organizations will occupy about 2000 booths. According to Clinical Lab Expo's Website, "You will see more products in every clinical lab discipline than at any other show." Find What You Need The Clinical Lab Expo will have special sections for special products. Visit the special sections for point-of-...
Last December, PwC released a new report, “Diagnostics 2011: M&A Surges, Companion Diagnostics Accelerate, and Early Detection Offers New Prospects.” This report provides an overview of merger and acquisition deal activity in the IVD industry during the past two years and the factors driving it, an assessment of the development of new prospects for early detection testing, and a review of significant events for the development of personalized medicine. The report also...
While the debate over healthcare reform continues to rage in the halls of Congress, IVD companies are working to maximize state-of-the-art care and thus help control costs. On the science side, researchers, physicians, and pharmaceutical companies are able to develop new methods and new drugs that are proving effective for treating a growing number of diseases including cancer, which is the second leading cause of death in the United States. While the pressure is on to control costs at all...
GE Healthcare purchased Clarient Inc. (Aliso Viejo, CA) late last year. The acquisition was announced in October; U.S. regulators approved the transaction the following month.  GE, a well-known player in diagnostic imaging, is looking to lengthen its reach into molecular diagnostics (MDx), particularly in the oncology realm. With its acquisition of Clarient, it gains the potential for playing a large, comprehensive role in diagnosing and treating cancer. “Clarient is a clear leader...
Life sciences had a solid third quarter of 2009 in venture capital (VC) investment relative to other industry sectors. A late-October report by PriceWaterhouseCoopers indicates that the biotech industry received the highest level of funding for all industries in the quarter with $905 million going into 104 deals. (The report includes private, emerging companies only.) This level of investment reflects a 4% decrease in dollars but a 16% increase in deals compared to the previous quarter, when...
    EMERGING IVD COMPANIES       Photo by iStockphoto Until recently, most people believed the healthcare industry would remain impervious to the ebbs and flows of the U.S. economy. However, 2008 saw an amazing number of layoffs in the pharmaceutical industry and more hospitals struggling to keep their doors open. Healthcare reform once seemed like an option, a decision that would or would not be made. Now, the question is not, “Yes or no to...